Patel Pooja, Giordano Antonio, Giordano Sara, Schlam Ilana, Tolaney Sara M, Tarantino Paolo
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
St. Elizabeth's Medical Center, Boston, MA, USA.
NPJ Breast Cancer. 2025 Jul 30;11(1):81. doi: 10.1038/s41523-025-00800-4.
Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with potent cytotoxic payloads, leading to improved tumor delivery of the latter. After improving outcomes for patients with metastatic disease, ADC testing moved to the curative setting, where already one agent (trastuzumab emtansine) has been approved, after demonstrating to improve overall survival. Herein, we review the rationale, evidence, and challenges with the use of ADCs in the early-stage setting.
抗体药物偶联物（ADCs）将单克隆抗体的特异性与强效细胞毒性药物结合，从而提高后者在肿瘤部位的递送效率。在改善转移性疾病患者的治疗结果后，ADCs的测试转向了治愈性治疗领域，在该领域，已经有一种药物（曲妥珠单抗-美坦新偶联物）在证明可提高总生存期后获得了批准。在此，我们综述了在早期治疗中使用ADCs的理论依据、证据和挑战。
